Category Archives: New Jersey Stem Cells

Tirapazamine (TPZ) with conventional trans-arterial chemoembolization had a good safety profile and promising efficacy signals in early- and intermediate-stage liver cancer, including in patients who had progression or recurrence after standard therapy

Of the 17 evaluable patients, including 10 who progressed despite prior therapy, 47% achieved complete response, with a median time to progression of 12.6 months and a median overall survival of 29.3 months

Results are consistent with the response rates seen in previous treatment-naive patient cohort, and support the theory that TPZ chemoembolization could induce complete tumor necrosis

The dose was selected for a randomized Phase 2 study to compare TPZ with doxorubicin, a current therapy, using the same embolization protocol

PRINCETON, N.J., and TAIPEI, Taiwan, June 21, 2022 (GLOBE NEWSWIRE) -- Teclison, a clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, today announced the peer-reviewed publication of a study demonstrating the safety, tolerability and preliminary efficacy of its trans-arterial tirapazamine chemoembolization (TATE) therapy in patients with unresectable early- and intermediate-stage hepatocellular carcinoma (HCC), also known as liver cancer. The clinical data, published in The Journal of Vascular and Interventional Radiology titled Phase I Dose-Escalation Study of Tirapazamine Chemoembolization for Unresectable Early- and Intermediate-Stage Hepatocellular Carcinoma, establishes tirapazamine, a hypoxia-activated anti-cancer drug, as safe when administered in conjunction with trans-arterial embolization with promising efficacy in patients with liver cancer, including those with progression or recurrence after treatment with conventional trans-arterial chemoembolization (TACE).

The current standard of care for unresectable liver cancer is conventional trans-arterial chemoembolization with the chemotherapeutic agent doxorubicin. Though well established, TACE with doxorubicin has limited efficacy because chemotherapy does not effectively kill cancer stem cells, a root cause for tumor recurrence after TACE. Additionally, embolization-induced tumor hypoxia is thought to dampen the cytotoxic effects of doxorubicin, said Chang-Hsien Liu, MD, principal investigator of the study. The results of this study support tirapazamine as an alternative to doxorubicin in trans-arterial chemoembolization. A future randomized study is warranted to compare tirapazamine and doxorubicin under embolization.

Ray Lee, MD, PhD, Founder and CEO of Teclison, added, We are encouraged by the potential of trans-arterial tirapazamine chemoembolization to improve the clinical response and extend overall survival when administered to patients with liver cancer. This data reinforces findings from our previous first-in-human study published in the Journal of Hepatocellular Carcinoma and establishes the tirapazamine dose for subsequent Phase 2 clinical trials.

Seventeen patients with unresectable early-stage HCC or unresectable intermediate-stage HCC were enrolled in this non-randomized, open-label Phase 1 study. Prior treatment such as surgery, radiofrequency ablation, and TACE, was permitted. Following a 3 + 3 dose escalation design, patients were assigned to three cohorts with a tirapazamine dose of 5mg/m2, 10mg/mg2 and 20mg/m2, respectively. As no dose-limiting toxicity was observed, the 20mg/m2 dose was converted to a fixed 35mg dose in the expansion cohort. The primary outcomes of the study were safety and tolerability. No serious adverse side effect was reported during the study. Most common adverse effects included transiently elevated liver enzymes, abdominal pain, fever, elevated bilirubin level, and transient ECG abnormality. The secondary endpoint was efficacy of TATE therapy. Of the 17 enrolled patients, 8 achieved complete response (CR 47.1%) as measured radiographically. Three patients achieved a partial response (PR 17.6%) for an overall response rate of 65%. CR rates were comparable between subgroups with and without prior TACE. The six-month progression-free survival rate was 72.6% and the median overall survival (OS) was 29.3 months.

Trans arterial chemoembolization (TACE) is the common therapeutic modality recommended by the Barcelona Clinic Liver Cancer (BCLC) staging system for patients with intermediate or advanced HCC. The overall response rate of TACE is 52% and median OS of about 20 months in a recent systemic review of 10,000 patients. A Phase 2 randomized study comparing efficacy of TATE vs TACE in patients with intermediate liver cancer is underway.

About TeclisonTeclison is a clinical-stage pharmaceutical company developing novel cancer therapeutics to induce targeted necrosis of solid tumors and convert the tumor into a therapeutic vaccine to enhance cancer remission. The Companys portfolio is comprised of new approaches aimed at enhancing the therapeutic benefit of immunotherapy to treat nearly all solid tumors. Its lead product candidate, TEC-001, a first-in-class therapeutic agent, and Trans-Arterial TEC-001 Embolization (TATE) therapy, are being evaluated in combination with FDA-approved immune checkpoint inhibitors in Phase 2 clinical trials for the treatment of liver, colorectal and lung cancer. Teclison is headquartered in Princeton, New Jersey. For more information, please visitwww.teclison.com.

Forward-Looking StatementsThis press release contains statements that are forward-looking statements that are based upon managements current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated herein.

Media contact:Gloria GasaaturaLifeSci CommunicationsTel: (646) 970-4688ggasaatura@lifescicomms.com

Read more from the original source:
Teclison Announces Publication of Phase 1 Data Demonstrating the Safety and Therapeutic Potential of Tirapazamine Chemoembolization for Patients with...

Recent research finds that the insulin receptor protein (INSR) is pivotal for brain stem cell longevity and growth.

Stem cells are the bodys raw materials they are the cells that give rise to all other cells with specialized functions. In the right circumstances, stem cells in the body divide to produce new cells known as daughter cells.

Humans contain neural stem cells in their brains. These brain stem cells may develop into neurons, astrocytes, or oligodendrocytes. Because neural stem cells generate all of the brains cell types, there is a multitude of stem cells in an embryos brain. In fact, the majority of brain cells are born in the embryo stage. These cells persist till adulthood and can be found in particular regions of the brain. Neural stem cells are essential for your brain to properly function.

According to research from Rutgers University, a receptor that was first identified as necessary for insulin action and is also found on neural stem cells found deep in the brains of mice is crucial for brain stem cell longevity, a finding that has important implications for brain health and future therapies for brain disorders.

The research, published in the journal Stem Cell Reports, focuses on a particular protein known as the insulin receptor (INSR), which is prevalent in neural stem cells in the brains subventricular zone. Neural stem cells give rise to the entire nervous system throughout development and persist into adulthood. Over the course of a persons life, these neural stem cells generate new neurons and non-neuronal cells that help the brains infrastructure and function.

Separately, while studying brain tumors, the researchers discovered that INSR plays an important role in the survival and maintenance of a population of specialized brain cancer cells known as glioblastoma (GBM) stem cells. They were able toreducethe growth of those primitive tumor-forming cells by inactivating the INSR in GBM stem cells.

Its important to understand the molecular mechanisms that are critical for the growth and sustenance of the brains stem cells under normal and abnormal growth states, said study author Steven Levison, a professor of neuroscience in the Department of Pharmacology, Physiology, and Neuroscience and director of the Laboratory for Regenerative Neurobiology at Rutgers New Jersey Medical School. Comprehending the signals that regulate these primitive cells could one day lead to new therapeutics for brain disorders.

Many neurodegenerative disorders, such as multiple sclerosis, Parkinsons disease, and Alzheimers disease, are connected with the destruction of brain cells, said co-author Teresa Wood, a Distinguished Professor and Rena Warshow Endowed Chair in Multiple Sclerosis in the Department of Pharmacology, Physiology, and Neuroscience at Rutgers New Jersey Medical School.

If we could influence how brain stem cells function then we can use this knowledge to replace diseased or dead brain cells with living ones, which would advance the treatment of neurological diseases and brain injuries, said Wood, who also teaches and conducts research at the Cancer Institute of New Jersey.

Cell receptors such as INSR are protein molecules that reside on the surfaces of cells. Substances, either natural or human-made, that open the lock of a receptor can spur a cell to divide, differentiate or die. By identifying which receptors perform these functions on specific cell types, and by understanding their structures and functions, scientists can design substances that act as keys to receptors, to turn them on or off.

Previous studies by this research team had shown that a certain key, the signaling protein that is known as the insulin-like growth factor-II (IGF-II), was necessary to maintain the neural stem cells in the two places of the adult brain that harbor these primitive cells. In the current experiment, scientists were looking to identify the receptor. To do so, they used genetic tools that allowed them to both delete the INSR and introduce a fluorescent protein so they could track the neural stem cells and the cells they generate. They found that the numbers of neural stem cells in the subventricular zone in the brains of mice lacking the INSR collapsed.

Adult neurogenesis the idea that new cells are produced in the adult brain has been a burgeoning field of scientific inquiry since the late 1990s, when researchers confirmed what had only been a theory in lab studies of human, primate, and bird brains. Neural stem cells in the adult are stem cells that can self-renew and produce new neurons and the supporting cells of the brain, oligodendrocytes, and astrocytes.

Given the widespread interest in stem cells as well as interest in whether alterations to adult stem cells might contribute to cancer, our research findings should be of interest, Levison said.

Other Rutgers authors included Shravanthi Chidambaram, Fernando J. Velloso, Deborah E. Rothbard, Kaivalya Deshpande, and Yvelande Cajuste of the Department of Pharmacology, Physiology, and Neuroscience at Rutgers New Jersey Medical School. Other participating investigators were at the University of Minnesota, the Albert Einstein College of Medicine, and Brown University.

Reference: Subventricular zone adult mouse neural stem cells require insulin receptor for self-renewal by Shravanthi Chidambaram, Fernando J. Velloso, Deborah E. Rothbard, Kaivalya Deshpande, Yvelande Cajuste, Kristin M. Snyder, Eduardo Fajardo, Andras Fiser, Nikos Tapinos, Steven W. Levison and Teresa L. Wood, 5 May 2022, Stem Cell Reports.DOI: 10.1016/j.stemcr.2022.04.007

The rest is here:
This Key Protein Is Essential for Brain Cell Longevity and Growth - SciTechDaily

New Jersey, United States-Worldwide Stem Cell Cartilage Regeneration Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2030 is a new report created by IBI. The worldwide foundational microorganism ligament recovery market report has been portioned based on undifferentiated cell type, treatment, end client, and district. Moreover, the mechanical progressions in ligament recovery and headways in immature microorganism-based tissue designing will introduce adequate learning experiences for the ligament recovery market to fill in the figure time of 2020 to 2027.

Stem-cell-based therapy is a significant figure in the practical substitution of ligament recovery. Immature microorganisms are classified into three sorts of cells in particular: hematopoietic undifferentiated organisms, mesenchymal undeveloped cells, and pluripotent undifferentiated cells. Rising reception of negligibly intrusive medical procedure methods, inferable from its advantages, for example, lower risk and more limited span for a medical procedure is a key element expected to drive the development of the immature microorganism ligament recovery market over the gauge period. Mesenchymal foundational microorganisms are the most generally applied undifferentiated cells in the field of ligament recovery.

Receive the Sample Report of Stem Cell Cartilage Regeneration Market Research Insights 2022 to 2030 @ https://www.infinitybusinessinsights.com/request_sample.php?id=801764

Competitive Analysis

Central members covered as a piece of this study incorporate Theracell Advanced Biotechnology Ltd., Orthocell Ltd., Xintela AB, CellGenix GmbH, Merck KGaA, Osiris Therapeutics, Inc., BioTissue SA, and Vericel Corporation.Experiences from this report would permit advertisers and the board specialists of organizations to pursue informed choices concerning their future item send-off, administrative drives, mechanical up-degree, market development, and showcasing strategies.

Division Segment

Division by Stem Cell type:

Hematopoietic Stem Cells (HSCs)Pluripotent Stem Cells (iPSC/ESCs)Mesenchymal Stem Cells (MSCs)

Division by treatment:

MicrofractureOsteochondral TransplantAutologous Chondrocyte ImplantationUndifferentiated organism Injections

Division by end client:

Medical clinics and ClinicsMobile Surgical Centers

Division by district:

North AmericaEuropeAsia PacificLatin AmericaCenter East and Africa

Coronavirus Impact AnalysisThe report shares our viewpoints on the effect of COVID-19 in the long and short term. The report gives the impact of the emergency on the business chain, particularly for promoting channels.

Download the Full Index of the Stem Cell Cartilage Regeneration Market Research Report 2022

For what reason Should You Buy This Report?

The present and estimated territorial market size information in view of utilization, types, and areas.Market patterns, drivers, and difficulties for the worldwide market.Examination of organization profiles of top key part working on the lookout.Definite market investigation and market valuationThe portion of the overall industry of the top central members and figure in view of the authentic and current information.

Contact Us:Amit JainSales Co-OrdinatorInternational: +1 518 300 3575Email: [emailprotected]Website: https://www.infinitybusinessinsights.com

Read the original here:
Stem Cell Cartilage Regeneration Market to Witness Massive Growth from 2022 to 2030 | Central members covered as a piece of this study incorporate...

New Jersey, United States TheStem Cell Therapy Marketreport is the result of extensive and expert research into theStem Cell Therapyindustry. TheStem Cell TherapyMarketreport explains what the market is all about, the market prognosis, several segmentations, and everything that falls under the markets umbrella. It also looks at major and secondary market drivers, market share, potential sales volume, regional analysis, and the markets key segments. The research also includes key variables that contribute to the markets growth as well as elements that might stifle the markets growth. The professionals at VM Reports applied precise research techniques and other analyses.

PESTLE analysis and SWOT analysis are two of the analyses utilized in theStem Cell TherapyMarketresearch, and they shed light on numerous internal and external variables that affect the market in every situation. It also includes a section that identifies strengths, weaknesses, opportunities, and threats, as well as Porters five forces model.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=24113

There is also a section dedicated to significant actors and their plans, such as acquisitions, collaborations, and so on. The material in the Stem Cell Therapy Market research was gathered mostly via expert opinions, interviews, and surveys. Verified Market Research experts have created a Stem Cell Therapy Market research that is full of clarity, accuracy, and useful information. The data in the report is quite accurate and reliable, with no duplicates or mistakes.

Key Players Mentioned in the Stem Cell Therapy Market Research Report:

Osiris Therapeutics Medipost Co. Ltd., Anterogen Co. Ltd., Pharmicell Co. Ltd., HolostemTerapieAvanzateSrl, JCR Pharmaceuticals Co. Ltd., Nuvasive RTI Surgical Allosource

Stem Cell TherapyMarket Segmentation:

Stem Cell Therapy Market, By Cell Source

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

Stem Cell Therapy Market, By Therapeutic Application

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

Stem Cell Therapy Market, By Type

Allogeneic Stem Cell Therapy Autologous Stem Cell Therapy

Inquire for a Discount on this Premium Report@ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113

Stem Cell Therapy Market Report Scope

Key questions answered in the report:

1. Which are the five top players of the Stem Cell Therapy market?

2. How will the Stem Cell Therapy market change in the next five years?

3. Which product and application will take a lions share of the Stem Cell Therapy market?

4. What are the drivers and restraints of the Stem Cell Therapy market?

5. Which regional market will show the highest growth?

6. What will be the CAGR and size of the Stem Cell Therapy market throughout the forecast period?

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/stem-cell-therapy-market/

Visualize Stem Cell Therapy Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Stem Cell Therapy Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Visit link:
Stem Cell Therapy Market Size, Scope and Forecast | Osiris Therapeutics Medipost Co. Ltd., Anterogen Co. Ltd., Pharmicell Co. Ltd.,...

JERSEY CITY, N.J., May 31, 2022 /PRNewswire/ --InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global ATMP Service Providers Marketby Type of Services (Analytics/CRO (Microbiology, Endotoxin, PCR, Flow Cytometry, ELISA, Container Closure, Sterilty, and Pre-clinical), Quality (Documentation, QMS And Regulations), CMO (HQ/GMP plasmid DNA, MSC Manufacture, Pluripotent Stem Cells), Logistics (Storage, Stability And Transport)), Application (GTMP(Gene Therapy Medicinal Products), sCTMP(somatic Cells Therapy Medicinal Products) and TEP(Tissue Engineered Products))-Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

InsightAce Analytic Pvt. Ltd. Logo

According to the latest research by InsightAce Analytic, the Global ATMP Service Providers Market is valued at US$ 13.85 Billion in 2021, and it is expected to reach US$ 34.59 Billion by 2030, with a CAGR of 10.9% during the forecast period of 2022-2030. By region, North America dominated the market with major market share in 2021.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1228

ATMPs, or Advanced Therapy Medicinal Products, are cutting-edge treatments created with specifically modified cells, genes, and tissues. ATMPs open the way to personalized and precise medicines that can prevent, diagnose, treat, or cure diseases at their source instead of more typical, one-size-fits-all drugs. They offer groundbreaking new opportunities to treat life-threatening diseases where one or limited doses have a curative effect. Characterization and analysis are essential in providing critical chemistry, manufacturing, and control (CMC) information for Investigational New Drug Applications in the case of ATMP services (INDs). Testing is also required as part of stability studies and to support release. Service providers support product development from early-stage to in-process control and product release assays.

The global prevalence is increasing regarding chronic diseases like diabetes, cancer, cardiovascular disease, and hereditary diseases like cystic fibrosis and others. As the demand for individualized medicine grows, technology advances in biological treatments, resulting in breakthrough Advanced Therapy Medicinal Products. This is a critical aspect of ATMP service providers' market expansion. Most new advanced therapy products are being developed in the US and EU. Companies will look for low-cost clinical trials in emerging markets that offer innovative opportunities to ATMP service providers. Huge investments by commercial and non-commercial sponsors in testing cell-based product candidates in clinical studies will also accelerate the service provider's market.

Story continues

However, ATMPs are expensive for patients, and health insurance schemes will slow down the market growth. Furthermore, several factors such as the lack of manufacturing capabilities to meet rising consumer demand and the resource and budget limitations faced by advanced therapy medicinal product developers have developed lucrative opportunities for contract services providers and increased market competition.

Geographically, North America accounted for the leading revenue share, followed by the Asia Pacific region, owing to the exponential rise in clinical trials of advanced therapies with significant investments. Also, strategic collaborations and a strong pipeline of ATMPs accelerates revenue generation in the region.

Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1228

Significant market players are Takara Bio, NorthX Biologics, Cellco Labs, AWA, ClinStorage, Key2Complience, Nordic BioAnalysis, YSDS, Truly Labs, ABC Labs, Mikrolabs, NDA group, Propharma group, Celonic, Bio Elpida, CGT Catapult, Rentschler Biopharma SE, AGC Biologics, WuXi Advanced Therapies, BlueReg, Minaris Regenerative Medicine, Patheon, Bio-Techne Corporation, bioMrieux SA, Catalent, Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Intertek Group plc, Lonza Group AG, Merck KGaA, Sartorius AG, SGS S.A., Sistemic Scotland Limited, Thermo Fisher Scientific Inc., Vigene Biosciences, Inc., WuXi AppTec and others.

Key Developments in the market

In Mar 2022, Rentschler Biopharma and Vetter Unveil Xpert Alliance. This strategic collaboration delivers effective solutions to address clients' changing and expanding needs in the area of complex biopharmaceuticals.

In Oct 2021, The Swedish government, through their Life Sciences department, announced a 36 million SEK investment to the Swedish Innovation agency (Vinnova) to establish an Innovation hub enabling the production of Advanced Therapy Medicinal Products (ATMPs) and DNA and RNA based vaccines.

In Sept 2021, Lonza announced plans to expand drug manufacturing capabilities at its Stein facility in Switzerland. Lonza's investment aims to expand its overall drug product development and manufacturing services.

In June 2021, Bio-Techne Corporation and Catamaran Bio announced an expansion of their collaboration to develop cell engineering and cell process technologies for use by Catamaran in the manufacturing of CAR-NK cell therapy products.

Market Segments

Global ATMP Service Providers Market, by Type of Service, 2022-2030 (Value US$ Mn)

Global ATMP Service Providers Market, by Application, 2022-2030 (Value US$ Mn)

Global ATMP Service Providers Market, by Region, 2022-2030 (Value US$ Mn)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

North America ATMP Service Providers Market, by Country, 2022-2030 (Value US$ Mn)

Europe ATMP Service Providers Market, by Country, 2022-2030 (Value US$ Mn)

Germany

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific ATMP Service Providers Market, by Country, 2022-2030 (Value US$ Mn)

India

China

Japan

South Korea

Australia & New Zealand

Latin America ATMP Service Providers Market, by Country, 2022-2030 (Value US$ Mn)

Brazil

Mexico

Rest of Latin America

Middle East & Africa ATMP Service Providers Market, by Country, 2022-2030 (Value US$ Mn)

For Customization @https://www.insightaceanalytic.com/customisation/1228

Other Related Reports Published by InsightAce Analytic:

Global Cell and Gene Therapy Bioassay Services Market

Global Regulatory T-Cell (Tregs) Therapies Market

Global iPSCs Manufacturing Services Market

Global Biopharmaceutical Excipient Manufacturing Market

Global Allogeneic Cell Therapy Manufacturing Market

Why should buy this report:

To receive a comprehensive analysis of the prospects for the Global ATMP Service Providers Market

To receive an industry overview and future trends of the ATMP Service Providers Market

To analyze the ATMP Service Providers Market drivers and challenges

To get information on the ATMP Service Providers Market Size (Value US$ Mn) forecast to 2030

Significant investments, mergers & acquisitions in the ATMP Service Providers Market industry

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:

InsightAce Analytic Pvt. Ltd.Tel.: +1 718 593 4405Email: info@insightaceanalytic.comSite Visit: http://www.insightaceanalytic.comFollow Us on LinkedInFollow Us On Facebook

Cision

View original content:https://www.prnewswire.com/news-releases/advanced-therapy-medicinal-products-atmp-service-providers-market-worth-34-59-billion-by-2030---exclusive-report-by-insightace-analytic-301557857.html

SOURCE InsightAce Analytic Pvt. Ltd.

More here:
Advanced Therapy Medicinal Products (ATMP) Service Providers Market worth $34.59 Billion by 2030 - Exclusive Report by InsightAce Analytic - Yahoo...

New Jersey, United States TheGene Therapy Marketreport is the result of extensive and expert research into theGene Therapyindustry. TheGene TherapyMarketreport explains what the market is all about, the market prognosis, several segmentations, and everything that falls under the markets umbrella. It also looks at major and secondary market drivers, market share, potential sales volume, regional analysis, and the markets key segments. The research also includes key variables that contribute to the markets growth as well as elements that might stifle the markets growth. The professionals at VM Reports applied precise research techniques and other analyses.

PESTLE analysis and SWOT analysis are two of the analyses utilized in theGene TherapyMarketresearch, and they shed light on numerous internal and external variables that affect the market in every situation. It also includes a section that identifies strengths, weaknesses, opportunities, and threats, as well as Porters five forces model.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=40223

There is also a section dedicated to significant actors and their plans, such as acquisitions, collaborations, and so on. The material in the Gene Therapy Market research was gathered mostly via expert opinions, interviews, and surveys. Verified Market Research experts have created a Gene Therapy Market research that is full of clarity, accuracy, and useful information. The data in the report is quite accurate and reliable, with no duplicates or mistakes.

Key Players Mentioned in the Gene Therapy Market Research Report:

Novartis AG, Biogen, Gilead Sciences MolMed S.p.A., Spark Therapeutics Orchard Therapeutics plc., SIBIONO, Bluebird bio Shanghai Sunway Biotech Co. Ltd., Human Stem Cells Institute.

Gene TherapyMarket Segmentation:

Gene Therapy Market, By Product

Viral Vectors Non-viral Vectors

Gene Therapy Market, By Indication

Neurological Diseases Cancer Hepatological Diseases Duchenne Muscular Dystrophy Other Indications

Gene Therapy Market, By Delivery Method

Ex vivo In vivo

Inquire for a Discount on this Premium Report@ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=40223

Gene Therapy Market Report Scope

Key questions answered in the report:

1. Which are the five top players of the Gene Therapy market?

2. How will the Gene Therapy market change in the next five years?

3. Which product and application will take a lions share of the Gene Therapy market?

4. What are the drivers and restraints of the Gene Therapy market?

5. Which regional market will show the highest growth?

6. What will be the CAGR and size of the Gene Therapy market throughout the forecast period?

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/gene-therapy-market/

Visualize Gene Therapy Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Gene Therapy Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Read more:
Gene Therapy Market Size, Scope and Forecast | Novartis AG, Biogen, Gilead Sciences MolMed SpA, Spark Therapeutics Orchard Therapeutics plc., SIBIONO,...

New Jersey, United States TheCell Isolation/Cell Separation Marketreport is the result of extensive and expert research into theCell Isolation/Cell Separationindustry. TheCell Isolation/Cell SeparationMarketreport explains what the market is all about, the market prognosis, several segmentations, and everything that falls under the markets umbrella. It also looks at major and secondary market drivers, market share, potential sales volume, regional analysis, and the markets key segments. The research also includes key variables that contribute to the markets growth as well as elements that might stifle the markets growth. The professionals at VM Reports applied precise research techniques and other analyses.

PESTLE analysis and SWOT analysis are two of the analyses utilized in theCell Isolation/Cell SeparationMarketresearch, and they shed light on numerous internal and external variables that affect the market in every situation. It also includes a section that identifies strengths, weaknesses, opportunities, and threats, as well as Porters five forces model.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=24186

There is also a section dedicated to significant actors and their plans, such as acquisitions, collaborations, and so on. The material in the Cell Isolation/Cell Separation Market research was gathered mostly via expert opinions, interviews, and surveys. Verified Market Research experts have created a Cell Isolation/Cell Separation Market research that is full of clarity, accuracy, and useful information. The data in the report is quite accurate and reliable, with no duplicates or mistakes.

Key Players Mentioned in the Cell Isolation/Cell Separation Market Research Report:

Beckman Coulter (Subsidiary of Danaher Corporation), Becton, Dickinson and Company, GE Healthcare (A Fully Owned Subsidiary of General Electric Company), Merck KGaA, Thermo Fisher Scientific Inc., Miltenyi Biotec, Others.

Cell Isolation/Cell SeparationMarket Segmentation:

Cell Isolation/Cell Separation Market, by Cell Type

Human Cells Animal Cells

Cell Isolation/Cell Separation Market, by Product

Consumables Instruments

Cell Isolation/Cell Separation Market, by Technique

Centrifugation-Based Cell Isolation Surface Marker-Based Cell Isolation Filtration-Based Cell Isolation

Cell Isolation/Cell Separation Market, by End User

Research Laboratories & Institutes Hospitals & Diagnostic Laboratories Cell Banks Biotechnology & Biopharmaceutical Companies

Cell Isolation/Cell Separation Market, by Application

Biomolecule Isolation Cancer Research Stem Cell Research Tissue Regeneration In Vitro Diagnostics Therapeutics

Inquire for a Discount on this Premium Report@ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24186

Cell Isolation/Cell Separation Market Report Scope

Key questions answered in the report:

1. Which are the five top players of the Cell Isolation/Cell Separation market?

2. How will the Cell Isolation/Cell Separation market change in the next five years?

3. Which product and application will take a lions share of the Cell Isolation/Cell Separation market?

4. What are the drivers and restraints of the Cell Isolation/Cell Separation market?

5. Which regional market will show the highest growth?

6. What will be the CAGR and size of the Cell Isolation/Cell Separation market throughout the forecast period?

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/cell-isolation-cell-separation-market/

Visualize Cell Isolation/Cell Separation Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Cell Isolation/Cell Separation Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Read the rest here:
Cell Isolation/Cell Separation Market Size, Scope and Forecast | Beckman Coulter (Subsidiary of Danaher Corporation), Becton, Dickinson and Company,...

Finding the perfect substitute for your meat seems like a mind twister. Its not just about taste; meat lovers considering a move to the artificial meats side will demand similar texture, tenderness, and smell. More importantly, scientists attribute the need for meat to its unique mixture. Rutgers University nutritional sciences expert Paul Breslin describes this as a blend of fat and umami, a Japanese word that means the savory or meaty taste of foods. Recreating such powerful stimuli hasnt been easy, but as the processes improve and investments pour into the alternative meats industry, the results will continue turning heads.

Countries like Israel and Singapore are at the forefront of meat alternatives, particularly cultured meats. Whether its a 3D printed substitute for fish, chicken, pork, or cows meat, these countries want them as part of their food services.

In 2021, Forbes clearly described how Singapore is in a race to attract meat alternative companies due to the lack of locally produced foods. The move is expected to help this very small, heavily urbanized island city-state in Southeast Asia attract plenty of alt-protein players to create a more resilient food ecosystem, which currently imports over 90% of its food.

On the Middle Eastern front, Israel is a powerhouse of alt-meat companies, racing to develop an alternative to just about any animal-derived product, from meat to milk and eggs. With roughly 100 alternative protein companies active in Israel, over 40 percent of those alone have the breakthrough technology that could shape the future of protein.

Here, we discuss the eight players leading the 3D printed meat revolution.

One of the pioneering firms in this up-and-coming segment is the Israeli startup Aleph Farms. It created the worlds first slaughter-free steak made from cow cells in 2018 and developed a scalable manufacturing 3D tissue engineering platform called BioFarm, to cultivate whole-muscle steaks. A year later, it gained prominence when its experiment aboard the International Space Station (ISS) resulted in the first-ever lab-grown meat in space.

Established in 2017, this Rehovot headquartered business raised over $131 million in funding from more than 20 investors, including Leonardo DiCaprio. Ahead of an initial market launch around the end of 2022, the company is heavily expanding. Earlier this year, it opened a 65,000-square-foot facility located at Stratasys building in Rehovot. It also grew its portfolio of cultivated meat by adding a new product line of cell-cultured collagen (coming to market in 2024) derived from the cells of living cows and eliminating the need to slaughter animals for its production.

Cultivated meat. Image courtesy of Aleph Farms.

After hearing about cultured beef and chicken, it wouldnt take long before a company developed a way to produce real seafood products directly from fish cells as nutritious as conventionally grown fish. Based in San Diego, California, BlueNalu relies on cellular aquaculture, a sustainable solution to farmed or wild-caught fish.

To create an artificial fish fillet, the scientists initially anesthetize the fish, and a tissue sample is removed with a biopsy. Then, the fish cells are placed in giant vats and fed special nutrients to help them multiply before being 3D printed. If the startup can scale production, it could supply fish alternatives to millions of people without the bones, mercury, microplastics, and antibiotics usually associated with fish today.

By challenging the global agricultural and seafood supply chain, BlueNalu is paving the way for cell-cultured seafood as a global solution and plans to commercialize its flagship products in 2023.

BlueNalu showcases four menu items of its cultured fish. Image courtesy of BlueNalu.

Aiming to provide sustainable animal protein, Shanghai startup CellX creates cultivated meat products and plans to sell them at the same price as animal meat by 2025. Last year, the business debuted its product prototype, the first Chinese-made cell-cultured meat with a fibrous and 3D structure. During testing for the prototype of its flagship minced pork product, CellX also demonstrated three other structural product prototypes, namely, chunks of pork granules, filamentous scaffolds, and 3D bioprinted product prototypes.

Focused initially on domestic Chinese pig breeds, CellX quickly expanded to beef and poultry. A pioneer in cellular agriculture, CellX has now partnered with German food tech company Bluu Seafood to find solutions for the future of food. To move forward with the plan of eliminating animal meats, CellX is at the forefront of advancing the necessary regulatory approvals in China that will parachute investment, research, and ultimately, production of cell-cultured meat. Considering that China is the worlds largest meat consumer, CellX founders Ziliang Yang and Ran Liu believe there is great potential for the alternative protein market.

Californian startup Eat Just is selling cultivated meat. Its first product, a cell-cultivated chicken called GOOD Meat, was approved in Singapore for sale a year ago and is available at select restaurants. To create it, they use stem cells from chicken eggs, which can be cultured into the desired product. Once they have grown into edible tissue, they are then used to create a form of ink used by a 3D printer to layer it into normal-looking food. This way, the startup can create chicken-like products that taste just as good.

Eat Just has been around since 2011 when founders Josh Tetrick and Josh Balk decided to venture into vegan mayo, eggs from plants, and overall plant-based alternatives to conventionally-produced egg products. Today, with over $460 million in funding under its belt, the business is looking at a post-money valuation of one to ten billion dollars, according to PrivCo. But, more importantly, its vision to build a food system that makes it easy for people to eat better is well on its way.

Cultured chicken bites by Eat Justs GOOD Meat brand. Image courtesy of Business Wire

Launched in 2018, Fork & Goode translate tissue engineering technologies to making cell-based animal products (notably pork meat) without slaughter, damage to the environment, and with significantly fewer natural resources than the traditional industries.

Like many of its competitors, Fork & Goode starts by taking a small sample (no slaughter required) of muscle cells from a live animal, in this case, a Berkshire pig living on a farm in New Jersey. Then cells receive the nutrient-rich feed, just like a pig would, and by the time the cells reach the desired yield, scientists harvest the meat. Finally, partner chefs add their own flair and cook Fork & Goode pork in their favorite recipes. The startup stands on the shoulders of Garbor Forgacss work. A theoretical physicist turned tissue engineer, Forgacs pioneered 3D bioprinting to build functional living structures, tissues, and organoids. Moreover, he is the scientific founder of the first commercial bioprinting company, Organovo (now being revitalized by its original CEO, Keith Murphy).

After branching off from Modern Meadow, a biotechnology company that uses biofabrication to create sustainable materials, the startup began making pure animal proteins and fats that are clean, traceable, and delicious. This new approach to growing food has landed the company over $3.5 million so far, and they could start commercializing culture pork meat soon.

This year, Future Meat Technologies hopes to commercialize delicious cultivated meat. The biotech startup is a spinoff out of the Hebrew University of Jerusalem and piggybacks on the work of biomedical engineer and entrepreneur Yaakov Nahmias. He is not just the founding director of the Alexander Grass Center for Bioengineering at the Hebrew University of Jerusalem and a faculty member at the Center for Engineering in Medicine at Harvard Medical School, but the first researcher to 3D print cells for the first commercial human-on-chip technology.

Through distributive manufacturing of fat and muscle cells (the core building blocks of meat), the business aims to transform global meat production into an animal-free reality. Following the opening of its first industrial cultured meat production facility in Rehovot, Israel, in June 2021, Future Meat began producing 500 kilograms of cultured meat products daily, equivalent to 5,000 hamburgers. According to the company, the small-scale production costs per pound of chicken and beef were $150 and $200, respectively, in 2019. However, the pilot production facility can bring down the cost of production to less than $10 per pound in 2022.

Future Meat Technologies makes cultured meat. Image courtesy of Future Meat Technologies.

At the forefront of 3D-printed alternative meats, MeaTech (NASDAQ: MITC) is ready to take over the cultivated meat industry. Its alternative to conventional farming and meat results from an advanced and proprietary process that starts by isolating bovine stem cells from tissue samples and multiplying them. Next, the Israeli business formulates bioinks compatible with its proprietary bioprinting technology to print a steak structure. Once printed, the product goes into an incubator to mature and form the MeaTech steak.

Focused on developing a genuine replacement for conventional steak that maximizes cell-based content rather than non-meat ingredients, MeaTechs cultivated steak comprises real, living muscle and fat cells and does not contain any soy or pea protein typically used in plant-based alternatives.

In 2021, the company acquired Peace of Meat, now its Belgian subsidiary, and established MeaTech Europe. Ending the year with the worlds largest-ever 3D printed cultivated steak, the company promises groundbreaking results. To propel the companys go-to-market strategy, MeaTech partnered with the BlueSoundWaves collective, led by Ashton Kutcher, and plans to open a pilot plant in Belgium to accelerate the production of cultured chicken fat.

MeaTechs bioprinted cultured meat. Image courtesy of MeaTech.

Singapores Shiok Meats works with 3D printing technology to add texture to synthesized lab-grown crustacean meat for human consumption. The first of its kind cultivated meat and seafood company in the country and the South-East Asia region, Shiok currently produces crustaceans like shrimps, crabs, and lobsters using cellular agriculture technology.

In early 2019, Shiok Meats unveiled its prototype, eight shrimp dumplings (Siew Mai) that cost S$5,000 ($3,600). Then a year later, it showcased the worlds first-ever cell-based lobster meat. Shiok is on track to commercially launch its cultivated crustaceans by 2023, at $50 per kilo. Likely to be in minced form, the final product will be launched in a premium restaurant in Singapore.

Stay up-to-date on all the latest news from the 3D printing industry and recieve information and offers from thrid party vendors.

Visit link:
8 Players Leading the 3D Printed Meat Revolution - 3DPrint.com

image:Human ES cell derived RASC (respiratory airway secretory cell transitioning to an Alveolar type 2 cell over time in culture view more

Credit: Penn Medicine

PHILADELPHIA A new type of cell that resides deep within human lungs and may play a key role in human lung diseases has been discovered by researchers at the Perelman School of Medicine at the University of Pennsylvania.

The researchers, who report their findings today in Nature, analyzed human lung tissue to identify the new cells, which they call respiratory airway secretory cells (RASCs). The cells line tiny airway branches, deep in the lungs, near the alveoli structures where oxygen is exchanged for carbon dioxide. The scientists showed that RASCs have stem-cell-like properties enabling them to regenerate other cells that are essential for the normal functioning of alveoli. They also found evidence that cigarette smoking and the common smoking-related ailment called chronic obstructive pulmonary disease (COPD) can disrupt the regenerative functions of RASCshinting that correcting this disruption could be a good way to treat COPD.

COPD is a devastating and common disease, yet we really dont understand the cellular biology of why or how some patients develop it. Identifying new cell types, in particular new progenitor cells, that are injured in COPD could really accelerate the development of new treatments, said study first author Maria Basil, MD, PhD, an instructor of Pulmonary Medicine.

COPD typically features progressive damage to and loss of alveoli, exacerbated by chronic inflammation. It is estimated to affect approximately 10 percent of people in some parts of the United States and causes about 3 million deaths every year around the world. Patients often are prescribed steroid anti-inflammatory drugs and/or oxygen therapy, but these treatments can only slow the disease process rather than stop or reverse it. Progress in understanding COPD has been gradual in part because micethe standard lab animalhave lungs that lack key features of human lungs.

In the new study, Morrisey and his team uncovered evidence of RASCs while examining gene-activity signatures of lung cells sampled from healthy human donors. They soon recognized that RASCs, which dont exist in mouse lungs, are secretory cells that reside near alveoli and produce proteins needed for the fluid lining of the airway.

With studies like this were starting to get a sense, at the cell-biology level, of what is really happening in this very prevalent disease, said senior author Edward Morrisey, PhD, the Robinette Foundation Professor of Medicine, a professor of Cell and Developmental Biology, and director of the Penn-CHOP Lung Biology Institute at Penn Medicine.

Observations of gene-activity similarities between RASCs and an important progenitor cell in alveoli called AT2 cells led the team to a further discovery: RASCs, in addition to their secretory function, serve as predecessors for AT2 cellsregenerating them to maintain the AT2 population and keep alveoli healthy.

AT2 cells are known to become abnormal in COPD and other lung diseases, and the researchers found evidence that defects in RASCs might be an upstream cause of those abnormalities. In lung tissue from people with COPD, as well as from people without COPD who have a history of smoking, they observed many AT2 cells that were altered in a way that hinted at a faulty RASC-to-AT2 transformation.

More research is needed, Morrisey said, but the findings point to the possibility of future COPD treatments that work by restoring the normal RASC-to-AT2 differentiation processor even by replenishing the normal RASC population in damaged lungs.

The research was supported by the National Institutes of Health (HL148857, HL087825, HL134745, HL132999, 5T32HL007586-35, 5R03HL135227-02, K23 HL121406, K08 HL150226, DK047967, HL152960, R35HL135816, P30DK072482, U01HL152978), the BREATH Consortium/Longfunds of the Netherlands, the Parker B. Francis Foundation, and GlaxoSmithKline.

###

Penn Medicineis one of the worlds leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of theRaymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nations first medical school) and theUniversity of Pennsylvania Health System, which together form a $8.9 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according toU.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $496 million awarded in the 2020 fiscal year.

The University of Pennsylvania Health Systems patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Centerwhich are recognized as one of the nations top Honor Roll hospitals byU.S. News & World ReportChester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nations first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 44,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2020, Penn Medicine provided more than $563 million to benefit our community.

Cells

Human distal airways contain a multipotent secretory cell that can regenerate alveoli

30-Mar-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

View original post here:
Penn researchers discover new cell type in human lung with regenerative properties - EurekAlert

A novel natural killer cell therapy is now on the fast track to FDA approval and being assessed in a phase 1 clinical trial.

The FDA has granted fast track designation to, CYNK-001, a novel on-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy for the treatment of patients with acute myeloid leukemia, according to a press release issued by Celularity Inc.1

CYNK-001 contains NK cells derived from human placental CD34+ cells and culture-expanded. In a new phase 1 multi-dose study (NCT04310592) of approximately 56 adult patients with AML, CYNK-001 cells will be given after lymphodepleting chemotherapy to determine its safety and whether NK cells be used to treat AML.1,2

The majority of patients with AML continue to have poor long-term outcomes, particularly those who suffer relapse or have measurable residual disease, necessitating development of novel therapies, including CYNK-001, said Andrew Pecora, MD, president of Celularity, in a press release.1

We believe that the unique properties of our cell source, including the ability to proliferate and maintain activity, could be the key to improving response rates and durability for patients. We are pleased to receive this fast-track designation from the FDA for AML supporting continued development of our placental-derived NK cell platform. CYNK-001 previously received orphan drug designation for malignant gliomas and fast track designation for glioblastoma multiforme, said Robert Hariri, MD, PhD, founder, chairperson, and chief executive officer of Celularity, in the press release.

In the phase 1 study of CYNK-001 the coprimary end points include dose-limiting toxicity (DLT) in minimal residual disease (MRD) positive patients with AML, DLT in relapsed or refractory patients with AML, the maximum-tolerated dose (MTD) in the MED -positive population, MTD in the relapsed/refractory population, and the frequency and severity of adverse events (AEs). Secondary end points that will be evaluated in the study include the number of patients who experienced MRD response, time to MRD response, duration of MRD response, progression-free survival, time to progression, duration of morphologic complete remission, overall survival, overall response rate, and duration of response.2

Patients aged 18 to 80 years with either primary/secondary AML or relapsed/refractory AML are eligible to enroll. Patients are required to have an ECOG performance status of 2 and must be able off immunosuppressive drugs for at least 3 days before CYNK-001 infusion. Both male and female patients are required to contraception during the study and females cannot be pregnant when enrolling. The study also permits the inclusion of patients with central nervous system involvement that has been treated and who have clear cerebral spinal fluid for at least 2 weeks before joining the study.

The study is actively recruiting adults with AML to at 8 centers across the United States, including in Colorado, Illinois, New Jersey, New York, Tennessee, Washington.

References:

1. Celularity receives fast track designation from U.S. FDA for its NK cell therapy CYNK-001 in development for the treatment of AML. News release. December 27, 2021. Accessed December 29, 2021. https://bit.ly/3sE9g1O

2. Natural killer cell (CYNK-001) infusions in adults with AML (CYNK001AML01). Clinicaltrials.gov. Accessed December 29, 2021.

Go here to see the original:
FDA Grants Fast Track Designation to CYNK-001 for AML Treatment - Targeted Oncology